- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03772158
Cetirizine Chewable Bioequivalence and Food Effect Study
November 29, 2021 updated by: Johnson & Johnson Consumer Inc., McNeil Consumer Healthcare Division
A Randomized, Single-Dose, Four-Treatment Crossover Bioequivalence and Food Effect Study of Test Formulation of Cetirizine 10mg Chewable Tablets Versus Two Marketed Cetirizine 10mg Immediate Release Tablets.
The purpose of this study is to determine and compare the amount of study drug that gets into your blood after the administration of each of the three formulations of cetirizine under different conditions.
Another objective of this study is to evaluate the effect of food on the amount of study drug that gets into your blood after the administration of the investigational formulation.
Other objectives of this study are to determine the sensory experience and ease of swallowing the investigational formulation, as well as to determine the safety of test and reference formulations of cetirizine.
Study Overview
Status
Completed
Conditions
Intervention / Treatment
Detailed Description
The purpose of this study is to establish bioequivalence of a cetirizine 10 mg chewable tablet manufactured at Johnson & Johnson Consumer Inc. (McNeil LLC) with two commercially marketed cetirizine 10 mg immediate release (IR) tablets (ZYRTEC®, US reference) and (Australian/EU reference), establish bioequivalence between the two commercial products (ZYRTEC®, US reference and REACTINE®, Australian/EU reference), and to evaluate the effect of food on bioavailability of the cetirizine 10 mg chewable tablet compared to the bioavailability of cetirizine 10 mg chewable tablet administrated with water only.
In addition, subject's sensory experience and ease of swallowing of the test product will be assessed.
Study Type
Interventional
Enrollment (Actual)
40
Phase
- Phase 1
Contacts and Locations
This section provides the contact details for those conducting the study, and information on where this study is being conducted.
Study Locations
-
-
Quebec
-
Mount-Royal, Quebec, Canada, H3P 3P1
- Algorithme (An altascience Company)
-
-
Participation Criteria
Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.
Eligibility Criteria
Ages Eligible for Study
18 years to 55 years (Adult)
Accepts Healthy Volunteers
No
Genders Eligible for Study
All
Description
Inclusion Criteria:
- Healthy male or female subject between the ages of 18 and 55 years, inclusive. Health is defined as the absence of clinically relevant abnormalities as judged by the Investigator on the basis of a detailed medical history, physical examination, blood pressure, pulse rate measurements, 12-lead electrocardiogram (ECG), as well as clinical laboratory tests. The responsible Investigator may request additional investigations or analyses if necessary.
- Non- or ex-tobacco user, being defined as someone who completely stopped smoking or using any form of tobacco or nicotine-containing product for at least 6 months before screening visit of this study.
- For females: Postmenopausal state (i.e. at least 1 year without menses without an alternative medical condition prior to the first study drug administration) or premenopausal /perimenopausal state with an effective means of contraception (as defined in Section 10.5.5).
- For males: No pregnant or lactating spouse or partner at screening and willingness to utilize an acceptable form of birth control with spouse or any potential partner during the study.
- Body Mass Index (BMI) ≥ 18.5 and ≤ 30 kg/m2 with a total body weight >50 kg.
- A personally signed and dated informed consent document, indicating that the subject has been informed of all pertinent aspects of the study.
- Is able to comprehend the requirements of the study (based upon clinical site personnel's assessment) and is willing and able to comply with scheduled visits, treatment plan, laboratory tests, and other study procedures specified within the protocol.
Exclusion Criteria:
- Use of prescription or non-prescription medications within 5 half-lives before the first IP administration unless these are contraceptives or occasional use of other medications approved by the Investigator.
- Use of any vitamins, dietary and herbal supplements within seven days before first dose of study drug.
- History of any allergy or hypersensitivity (e.g. skin reaction, asthma, angioedema) to cetirizine or any excipients of the formulations.
- If female: is pregnant, has a positive pregnancy test at screening or prior to the first study drug administration, or is planning to become pregnant during the duration of the study, and/or is breast-feeding.
- Has a history of gastrointestinal surgery other than appendectomy.
- Has hypertension, fluid retention, or heart disease either by history or by the medically qualified Investigator's medical judgment.
- Currently suffering from asthma or has a medically significant history of asthma in the opinion of the investigator.
- Has clinically significant renal or hepatic impairment; according to the medically qualified Investigator discretion.
- Was treated with an investigational product within 28 days or within a period less than 5 times the drug's half-life, whichever is longer, preceding the first dose of study drug.
- Preplanned surgical procedures during the study period as this may interfere with the conduct of the study.
- History of alcoholism or substance abuse, as judged by the Investigator, within the past 6 months preceding this study.
- Consumed alcohol beverage(s) within 48 hours preceding the first dose of study drug.
- History of rare hereditary problems of galactose and/or lactose intolerance, lactase deficiency or glucose-galactose malabsorption.
- Any history of tuberculosis.
- Donation or loss of blood within 28 days prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 50 mL.
- Donation or loss of blood within 56 days prior to the first treatment visit if the estimated lost blood volume equaled or exceeded 500 mL.
- Has any acute or chronic medical or psychiatric condition(s) that may increase the risk associated with study participation or IP administration or may interfere with the interpretation of study results and, in the judgment of the medically qualified Investigator, would make the subject inappropriate for entry into this study.
- Relationship to persons involved directly in the conduct of the study (i.e., principal Investigator, sub-Investigators, study coordinators, other study personnel, employees or contractors of the sponsor or Johnson & Johnson subsidiaries, and the family of each).
- Has any clinically important abnormal value for serum chemistry, hematology, or urinalysis at screening. Laboratory values will generally be within the normal ranges, although minor deviations in tests (except those explicitly specified in the inclusion criteria) that are not considered clinically important by the Investigator are acceptable.
- Has a positive test for human immunodeficiency virus (HIV) 1 and 2 antibodies, hepatitis B surface antigen (HBsAg), or hepatitis C antibodies (anti-HCV).
- Has a positive test for alcohol or drugs of abuse at screening or prior to the first study drug administration.
Study Plan
This section provides details of the study plan, including how the study is designed and what the study is measuring.
How is the study designed?
Design Details
- Primary Purpose: Other
- Allocation: Randomized
- Interventional Model: Crossover Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: Treatment A
Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
Subjects will be instructed to chew the tablet completely before swallowing.
|
Chewable tablet
Other Names:
|
Experimental: Treatment B
Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast without water.
Subjects will be instructed to chew the tablet completely before swallowing.
|
Chewable tablet
Other Names:
|
Experimental: Treatment C
Single dose of 10 mg cetirizine as a chewable tablet, administered orally after a 10-hour overnight fast and 30 minutes after the start of the standard high-fat breakfast and followed with 240 mL ambient water.
Subjects will be instructed to chew the tablet completely before swallowing.
|
Chewable tablet
Other Names:
|
Active Comparator: Treatment D
Single dose of currently marketed US 10 mg cetirizine as immediate release tablet (ZYRTEC®), administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
|
Immediate Release Tablet
Other Names:
|
Active Comparator: Treatment E
Single dose of currently marketed EU/Australian 10 mg cetirizine film coated tablet (REACTINE®) administered orally after a 10-hour overnight fast and followed with 240 mL ambient water.
|
Immediate Release Tablet
Other Names:
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
The maximum observed plasma concentration (Cmax) of cetirizine
Time Frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
The maximum observed plasma concentration.
|
At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
The area under the plasma concentration versus time curves to the last measurable concentration (AUCt)
Time Frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
Area under the plasma concentration versus time curve from start of drug administration until last measurable concentration.
|
At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
Secondary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
---|---|---|
Area under the plasma concentration versus time curve extrapolated to infinity
Time Frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
Area under the plasma concentration-time curve extrapolated to infinity.
|
At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
The time point at which the maximum concentration of cetirizine is observed (Tmax).
Time Frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
The time point at which the maximum concentration of cetirizine occurs.
|
At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
The terminal elimination half-life (T1/2) of cetirizine in plasma
Time Frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
The time it takes for the cetirizine plasma concentration to fall to half of its original value.
|
At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
The terminal elimination rate constant (lambda z) for cetirizine in plasma.
Time Frame: At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
The rate at which the drug is removed from the body system.
|
At baseline, 0.25, 0.5, 0.75, 1, 1.25, 1.5, 2, 3, 4, 6, 8, 12, 24, 28 and 32 hours after the start of dose administration.
|
To assess subject's sensory experience and ease of swallowing of the test product
Time Frame: Assessed one minute after dosing, and preferably completed within 15 minutes of dosing for treatments A, B and C
|
A questionaire with 5 product sensory questions for study subjects to answer.
|
Assessed one minute after dosing, and preferably completed within 15 minutes of dosing for treatments A, B and C
|
Number of patients with adverse events.
Time Frame: Approximately 3 months. From signed informed consent until 30 days after last treatment administration.
|
An adverse event is any untoward medical occurrence in a subject after they have signed an informed consent for a trial involving an investigational product.
|
Approximately 3 months. From signed informed consent until 30 days after last treatment administration.
|
The extrapolated part of the area under the plasma concentration versus time curve of cetirizine
Time Frame: Extrapolated from 12 hours after start of drug administration until 48 hours
|
The area under the plasma concentration versus time curve from 12 hours after start of drug administration until 48 hours after start of drug administration.
|
Extrapolated from 12 hours after start of drug administration until 48 hours
|
Collaborators and Investigators
This is where you will find people and organizations involved with this study.
Publications and helpful links
The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.
Helpful Links
Study record dates
These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.
Study Major Dates
Study Start (Actual)
December 11, 2018
Primary Completion (Actual)
February 3, 2019
Study Completion (Actual)
February 3, 2019
Study Registration Dates
First Submitted
December 10, 2018
First Submitted That Met QC Criteria
December 10, 2018
First Posted (Actual)
December 11, 2018
Study Record Updates
Last Update Posted (Actual)
December 1, 2021
Last Update Submitted That Met QC Criteria
November 29, 2021
Last Verified
November 1, 2021
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- CCSURA000499
Plan for Individual participant data (IPD)
Plan to Share Individual Participant Data (IPD)?
Undecided
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Yes
Studies a U.S. FDA-regulated device product
No
product manufactured in and exported from the U.S.
Yes
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Allergy
-
University of RochesterNational Institute of Allergy and Infectious Diseases (NIAID)Not yet recruitingEgg Allergy | Food Allergy Peanut | Food Allergy in Infants | Allergy and Immunology | Peanut and Nut AllergyUnited States
-
Hong Kong Sanatorium & HospitalChinese University of Hong KongTerminatedAllergy to Fish | Allergy to Shrimp | Allergy to CrabHong Kong
-
Abionic SAJohns Hopkins University; NAMSAWithdrawnAllergy | Allergic Asthma | Allergy to Cats | Allergy to House Dust | Allergy Cockroach | Allergy to Dog Dander (Finding) | Allergy MoldUnited States
-
Peking University Third HospitalCancer Institute and Hospital, Chinese Academy of Medical Sciences; Beijing... and other collaboratorsRecruitingCow Milk Allergy | Food Allergy in ChildrenChina
-
King's College LondonGuy's and St Thomas' NHS Foundation TrustUnknownEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
King's College LondonKing's College Hospital NHS Trust; University College London Hospitals; Cambridge... and other collaboratorsRecruitingEgg Allergy | Food Allergy | Food Allergy in Children | Milk Allergy | Food Allergy in Infants | Nut Allergy | Food Allergen SensitisationUnited Kingdom
-
Chinese University of Hong KongRecruiting
-
Vilnius UniversityEnrolling by invitationFood Allergy in Children | Food Allergy in InfantsLithuania
-
Martini Hospital GroningenRecruitingCow Milk Allergy | Food AllergyNetherlands
-
University GhentActive, not recruitingCow Milk Allergy | Food AllergyBelgium
Clinical Trials on Cetirizine 10mg
-
GlaxoSmithKlineCompletedRhinitis, Allergic, SeasonalGermany
-
GlaxoSmithKlineCompletedRhinitis, Allergic, SeasonalGermany
-
Seattle Gummy CompanyFrontage Clinical Services, Inc.; Frontage Laboratories, Inc.Not yet recruiting
-
Novartis PharmaceuticalsCompletedAllergic RhinitisCanada
-
Hanmi Pharmaceutical Company LimitedCompletedPrimary HypercholesterolemiaKorea, Republic of
-
Dong-A ST Co., Ltd.Completed
-
UCB PharmaCompleted
-
Vigonvita Life SciencesCompletedErectile DysfunctionChina
-
Yokohama City UniversityRecruiting
-
International University of Health and WelfareTerminated